What Is PEPT (Proton-Coupled Oligopeptide Transporter)?

PEPT, short for proton-coupled oligopeptide transporter, is a type of membrane protein that ferries small peptide fragments into cells by riding the natural flow of protons (hydrogen ions) across cell membranes. In mammals, this family includes four members, with the two best studied being PepT1 and PepT2, which serve as the body’s principal route for absorbing protein-derived nutrients from food and for reclaiming those nutrients in the kidneys before they are lost in urine.¹ But these transporters do far more than handle nutrition. They also shuttle certain drugs into the body, participate in immune signaling, influence gut hormone release, and show up in unexpected places like the brain and skin.

The SLC15 Family at a Glance

Formally, PEPT transporters belong to the solute carrier family 15, or SLC15. This family has four mammalian members: PepT1 (SLC15A1), PepT2 (SLC15A2), PhT1 (SLC15A4), and PhT2 (SLC15A3).² All four share a common trick: they use the electrochemical gradient of protons across a membrane as fuel to pull their cargo inside a cell. The cargo they carry consists mainly of di- and tripeptides, meaning protein fragments made up of two or three amino acids linked together. Some also carry peptide-like drugs and bacterial-derived peptides.

PepT1 and PepT2 handle the heavy lifting for nutrient absorption. They sit on the outer surface of cells that line the gut and kidney, respectively. PhT1 and PhT2 are less well characterized but have distinct roles: PhT1 lives on the membranes of compartments inside immune cells, and PhT2 also localizes to intracellular membranes in various tissues. Despite sharing a common ancestor and a proton-driven engine, each member has evolved to serve a different tissue and a different physiological purpose.

How the Proton Engine Works

The “proton-coupled” part of the name is the key to understanding how these transporters function. After you eat a meal and stomach acid enters the upper intestine, the environment near the gut lining is slightly acidic. That acidity means there are more protons outside the cell than inside it, creating a gradient. PepT1 harnesses this gradient by allowing a proton to flow into the cell and, in the same motion, dragging a peptide molecule along for the ride. The process is sometimes described as symport, since both the proton and the peptide move in the same direction.³

An important partner in this system is a separate protein called NHE3, a sodium-hydrogen exchanger that sits alongside PepT1 on the cell surface. NHE3 pumps protons back out of the cell in exchange for sodium ions, effectively recycling the proton gradient that PepT1 depends on. When researchers blocked NHE3 in mouse intestines, peptide absorption dropped significantly, confirming that PepT1 does not work in isolation.⁴ Experiments in cultured cells found that coexpressing NHE3 alongside PepT1 roughly tripled the transport capacity, suggesting the two proteins form a cooperative unit on the cell membrane.⁵

Structural studies using cryo-electron microscopy have captured PepT1 and PepT2 in multiple snapshots throughout their transport cycle, revealing how the transporter opens to the outside of the cell, grabs a peptide, closes, and then opens inward to release the peptide into the cell’s interior.⁶ This alternating-access mechanism is a common theme in membrane transport biology, but the PEPT family is unusual in how promiscuous it is: PepT1 alone can recognize thousands of different di- and tripeptide combinations, plus a range of drug molecules that happen to resemble peptides structurally.

PepT1 in the Gut

PepT1 is the dominant peptide transporter in the small intestine. It sits in the brush-border membrane, the densely folded surface of intestinal cells that maximizes absorptive area. When you digest proteins from food, enzymes in the stomach and small intestine break them down into a mix of individual amino acids and small peptides. The small peptides, especially dipeptides and tripeptides, are absorbed primarily through PepT1 rather than through the separate amino acid transporters.⁷ In fact, peptide absorption through PepT1 is considered a major pathway for total dietary protein uptake, not a minor backup route.

The abundance of PepT1 in the gut is not fixed. It responds to diet and disease. A high-protein diet, for example, can upregulate PepT1 expression, while fasting or malnutrition can alter it in the opposite direction.⁸ This adaptability makes PepT1 a dynamic part of the digestive system rather than a static gateway.

PepT2 in the Kidney and Brain

While PepT1 dominates absorption in the gut, PepT2 handles a different job in different tissues. In the kidney, PepT2 sits in the lining of the kidney tubules and reabsorbs filtered peptides and peptide-like drugs, pulling them back into the body before they can be excreted. In the brain, PepT2 plays a housekeeping role by clearing peptides and peptide-like substances from the cerebrospinal fluid, the liquid that bathes the brain and spinal cord.⁹

The brain role has practical implications for drug treatment. In mice engineered to lack PepT2, the antibiotic cefadroxil accumulated to roughly two to two-and-a-half times higher levels in the fluid surrounding brain cells compared to normal mice.¹⁰ PepT2 was actively removing the drug from the brain fluid and shuttling it into brain cells or back toward the bloodstream. For drugs that need to reach the brain, PepT2 acts as a gatekeeper. For drugs that might be neurotoxic, that gatekeeping could be protective. Understanding how PepT2 handles specific drugs is an active area of pharmacology research.

Why Drug Designers Care About PEPT Transporters

One of the most commercially successful applications of PEPT biology is the prodrug strategy. A prodrug is a medication designed to be inactive or poorly absorbed on its own, but once it enters the body, enzymes convert it into the active form. If you can attach a chemical handle to a drug that makes it look like a dipeptide, PepT1 in the gut will absorb it far more efficiently than the drug alone.

The antiviral medication valacyclovir is a textbook example. Valacyclovir is the valine ester prodrug of acyclovir, a drug used to treat herpes simplex and other viral infections. Acyclovir by itself is poorly absorbed when taken orally. By attaching a valine amino acid to it, pharmaceutical chemists made it a substrate for PepT1. Studies in mice lacking PepT1 confirmed this: without the transporter, the rate and amount of valacyclovir absorbed from the gut dropped dramatically compared to normal mice, providing definitive evidence that PepT1 is the reason the prodrug strategy works for this medication.¹¹

Valacyclovir is not alone. Several beta-lactam antibiotics (the penicillin and cephalosporin families) are also recognized by PepT1, which helps explain their good oral bioavailability. Drug developers continue to explore PepT1-targeted prodrug strategies for new compounds, essentially hijacking the body’s nutrient absorption system to get medications through the gut wall.

Genetic Variation and Its Consequences

People do not all carry identical versions of SLC15A1 and SLC15A2 genes. Natural genetic variants, or polymorphisms, can alter how well PepT1 and PepT2 function. This matters because a less active transporter could mean lower drug absorption or different patterns of kidney handling for drugs that depend on these carriers.

In a study of critically ill patients receiving the antibiotic colistin, researchers screened for genetic variants in several transporter genes, including SLC15A1 and SLC15A2. They identified specific variants that were associated with a higher incidence of acute kidney injury during early treatment.¹² The implication is that some patients may be genetically predisposed to side effects from peptide-like drugs because their transporters handle those drugs differently. Pharmacogenomics, the study of how genes influence drug responses, is still in its early stages for the PEPT family, but findings like these suggest it could eventually inform dosing decisions.

PEPT Transporters and Immune Signaling

Beyond nutrition and drug transport, PEPT transporters have an unexpected role in the immune system. Bacteria produce short peptides, including a molecule called muramyl dipeptide (MDP), a fragment of bacterial cell walls. MDP is recognized by an intracellular immune sensor called NOD2, which triggers inflammatory responses when it detects signs of bacterial invasion. But MDP first needs to get inside the cell, and PEPT transporters provide the entry route.

In the skin, researchers found that PepT1 and PepT2 are expressed in different layers of the epidermis as skin cells mature. When PepT1 was knocked down in differentiated skin cells, the inflammatory response triggered by MDP dropped, showing that PepT1 was responsible for ferrying the bacterial peptide inside so NOD2 could detect it.¹³ This means PEPT transporters are part of the body’s microbial surveillance system, not just its nutrient absorption machinery.

Inside immune cells, the picture gets more complex. PhT1 (SLC15A4), one of the less-studied family members, sits on the membranes of lysosomes, the compartments where immune cells break down engulfed material. PhT1 transports histidine and various bacterial peptides, and it also serves as a scaffold for signaling molecules involved in inflammatory and metabolic pathways. Dysfunction in PhT1 has been linked to autoimmune conditions, including systemic lupus erythematosus.¹⁴

The Inflammatory Bowel Disease Connection

In healthy people, PepT1 is found almost exclusively in the small intestine. The colon expresses little to none of it under normal circumstances. But in people with inflammatory bowel disease, specifically Crohn’s disease and ulcerative colitis, PepT1 expression appears in the colon where it does not normally belong.¹⁵ Studies examining tissue samples from patients with chronic ulcerative colitis and Crohn’s disease confirmed this aberrant colonic expression, while normal colon tissue and tissue from patients with microscopic colitis showed no PepT1.¹⁶

Why does this matter? The colon is home to dense bacterial populations. If PepT1 starts appearing there, it can transport bacterial-derived peptides into colonic cells, potentially amplifying inflammatory signaling through pathways like NOD2. This could create a vicious cycle: inflammation drives PepT1 expression in the colon, and PepT1 then transports bacterial peptides that provoke more inflammation. Whether PepT1 is a cause, a consequence, or a contributor that worsens existing disease is still debated, but its aberrant presence in inflamed colonic tissue is well documented.¹⁷

Peptide Sensing, Gut Hormones, and Appetite

PepT1 does more than just ferry nutrients across the gut lining. It also appears to function as a sensor that tells hormone-producing cells in the gut that protein digestion products have arrived. When dipeptides and tripeptides are taken up through PepT1, the proton flux and associated changes in intracellular chemistry can trigger the release of gut hormones, including GLP-1 (glucagon-like peptide-1), a hormone with major effects on insulin secretion and appetite.

In mouse studies, di- and tripeptides stimulated GLP-1 secretion from intestinal cells in a PepT1-dependent manner. Researchers demonstrated this by using a non-metabolizable dipeptide (glycylsarcosine) that PepT1 recognizes but the cell cannot break down. In tissue from mice lacking PepT1, the GLP-1 response was impaired, confirming the transporter’s role.¹⁸ Other gut hormones implicated in PepT1-mediated protein sensing include cholecystokinin (CCK) and peptide YY (PYY), both of which influence satiety and the pace of digestion.¹⁹ This connection positions PepT1 as a link between dietary protein intake and the hormonal signals that regulate blood sugar and how full you feel after a meal.

PEPT Transporters in Cancer Imaging

Because PepT1 is overexpressed in various types of tumor cells, it has attracted interest as a target for cancer detection. Researchers developed a PET imaging tracer based on glycylsarcosine, the same non-metabolizable dipeptide used in laboratory studies, labeled with a radioactive carbon atom. In preclinical testing, this tracer was taken up by tumor cells through their PEPT transporters and showed a notable advantage over the standard PET tracer (FDG) in distinguishing tumors from sites of ordinary inflammation, which is a persistent challenge in cancer imaging.²⁰ The approach remains experimental, but the logic is appealing: if many cancer types express PepT1, a single transporter-targeted tracer could flag a wide range of malignancies.

An Ancient Family Found Across Kingdoms of Life

PEPT transporters are not a recent evolutionary invention. The broader family, often called the POT (proton-dependent oligopeptide transporter) superfamily, spans nearly all branches of life. Members have been found in bacteria, fungi, plants, and animals, though they are absent from archaea.²¹ The core proton-coupled mechanism and the basic structural architecture are conserved across these organisms, indicating the family arose very early in evolutionary history.²²

What makes the evolutionary story particularly interesting is how the family has diversified in different kingdoms. In mammals and bacteria, these transporters are predominantly peptide carriers. In plants, however, the same family has been repurposed dramatically: plant POT members transport nitrate (a crucial nutrient for plant growth), defense compounds, and hormones. Crystal structures from bacterial and plant members show that the ligand-binding site retains conserved features even as the substrates have diverged wildly.²¹ This is a useful reminder that evolution tends to repurpose successful molecular machines rather than build new ones from scratch.

The Bidirectional Surprise

For years, researchers assumed PEPT transporters worked as one-way valves, pulling peptides into cells. But electrophysiology experiments revealed that PepT1 can also run in reverse, pumping peptides back out of the cell. When frog egg cells expressing PepT1 were loaded with a dipeptide that resists being broken down inside the cell, large outward transport currents were recorded, meaning PepT1 was exporting the peptide rather than importing it.²³ Under normal conditions, imported dipeptides are quickly broken down into individual amino acids inside the cell, so the transporter rarely encounters enough intact intracellular peptide to drive efflux. But when that breakdown is blocked, the reverse mode becomes apparent. Whether this bidirectional capability has a physiological role in human tissue or remains primarily a laboratory curiosity is an open question, though it could influence how drugs that resist intracellular metabolism are handled.